HC Wainwright & Co. Reiterates Buy on ADMA Biologics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on ADMA Biologics (NASDAQ:ADMA) and maintained a $6 price target.
February 29, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on ADMA Biologics with a $6 price target.
The reiteration of a Buy rating and maintenance of a $6 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the company's future performance. This endorsement can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100